Trials / Active Not Recruiting
Active Not RecruitingNCT06412848
JAVEMACS: Japan AVElumab Maintenance And Continuous Treatment Study
A Multicenter, Retrospective, Observational Study of Avelumab Maintenance and Subsequent Therapies in Japanese Patients With Locally Advanced or Metastatic Urothelial Carcinoma
- Status
- Active Not Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 360 (actual)
- Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is a multicenter, non-interventional, retrospective, medical chart review of locally advanced or metastatic (la/m) Urothelial Cancer UC participants who were prescribed avelumab as first line maintenance therapy after a platinum-based chemotherapy. This study aims to understand the index date (i.e., at the initiation of avelumab maintenance therapy) demographics and clinical characteristics of participants with locally advanced/metastatic Urothelial Carcinoma in Japan, and to describe their treatment patterns and outcomes.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Avelumab | This is an observational study, participants who received avelumab as first line maintenance therapy after a PBCT. |
Timeline
- Start date
- 2024-05-09
- Primary completion
- 2026-06-30
- Completion
- 2026-06-30
- First posted
- 2024-05-14
- Last updated
- 2026-02-24
Locations
26 sites across 1 country: Japan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06412848. Inclusion in this directory is not an endorsement.